Maxim lowered the firm's price target on SeaStar Medical to $6 from $10 and keeps a Buy rating on the shares. The firm cites the company having announced the publication of positive early post-approval clinical experience from the use of the QUELIMMUNE therapy in the peer-reviewed journal of Pediatric Nephrology, though its price target reflects SeaStar's share dilution, the analyst tells investors in a research note.
